FibroGen (NASDAQ:FGEN – Get Rating) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.16, Briefing.com reports. FibroGen had a negative net margin of 109.22% and a negative return on equity of 109.09%. The business had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same period in the prior year, the firm earned ($1.45) EPS. The business's revenue for the quarter was up 22.3% on a year-over-year basis.
FibroGen Stock Performance
Shares of FGEN stock opened at $14.12 on Wednesday. The company has a market cap of $1.32 billion, a PE ratio of -4.64 and a beta of 0.87. FibroGen has a fifty-two week low of $7.81 and a fifty-two week high of $16.91. The stock's fifty day moving average price is $11.53 and its two-hundred day moving average price is $11.99.
Get
FibroGen alerts:
Hedge Funds Weigh In On FibroGen
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in FibroGen by 3.5% during the first quarter. Vanguard Group Inc. now owns 9,349,957 shares of the biopharmaceutical company's stock valued at $112,387,000 after buying an additional 313,769 shares during the period. State Street Corp lifted its position in FibroGen by 9.3% during the first quarter. State Street Corp now owns 4,927,781 shares of the biopharmaceutical company's stock valued at $59,232,000 after acquiring an additional 420,828 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock worth $28,799,000 after acquiring an additional 1,094,403 shares during the period. Dimensional Fund Advisors LP grew its position in shares of FibroGen by 204.5% in the first quarter. Dimensional Fund Advisors LP now owns 732,183 shares of the biopharmaceutical company's stock valued at $8,801,000 after purchasing an additional 491,722 shares during the period. Finally, Renaissance Technologies LLC raised its stake in FibroGen by 594.1% during the first quarter. Renaissance Technologies LLC now owns 687,900 shares of the biopharmaceutical company's stock worth $8,269,000 after purchasing an additional 588,800 shares during the period. Hedge funds and other institutional investors own 77.35% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on FGEN. The Goldman Sachs Group cut their target price on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a report on Tuesday, May 24th. StockNews.com raised FibroGen from a "hold" rating to a "buy" rating in a report on Tuesday, July 19th.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- CVS and Walgreens Show Why Investment Objectives Matter
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
